Nivolumab plus brentuximab vedotin for relapsed/refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma.
Blood Adv
; 8(10): 2400-2404, 2024 May 28.
Article
in En
| MEDLINE
| ID: mdl-38531062
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Lymphoma, T-Cell, Cutaneous
/
Lymphoma, T-Cell, Peripheral
/
Nivolumab
/
Brentuximab Vedotin
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Blood Adv
Year:
2024
Type:
Article
Affiliation country:
Italy